Enhanced Next-Generation Genomic Analysis Technology

Applied Biosystems has announced the commercial availability of the SOLiD™ 3 Plus System, an enhanced next-generation genomic analysis platform designed to allow researchers to move one step closer to
performing mainstream sequencing of personal genomes for clinical research and personalised medicine. The technical enhancements to SOLiD 3 Plus include higher throughput, decreased run costs, and
faster data analysis which deliver on a roadmap that enables scientists to sequence entire genomes in a more cost-effective and easy manner.

The SOLiD 3 Plus System, distinguished by its unmatched accuracy, is capable of generating more than 60 gigabases of mappable sequence data per run, at a 20% lower cost per sequencing run than previously
possible. The combination of increased throughput, which equates to an approximate 50% decrease in cost per gigabase, shorter run times, and improved data analysis makes the SOLiD technology the ideal choice
for large-scale resequencing genomic projects.

An advanced software solution, BioScope™, has been introduced and provides an integrated framework for data analysis, which allows researchers to benefit from smaller data files sizes while delivering faster mapping
times. The addition of BioScope enables researchers to export data into a standard base sequence format, enabling the combination of data from multiple sequencing platforms into a single project-based analysis, and allows direct comparison of data from multiple next-generation sequencing platforms. This has proven to be beneficial in large-scale genomic studies, such as the 1000 Genomes Project.